Synarc公司研制检测软骨退化的生物指标

一种反应关节组织降解的新型生化指标，被设计在关节炎新型治疗方法的临床试验中使用。

这种免疫分析方法叫做Syncart（helix-II），反应尿液中II型胶原的降解片段。II型胶原的降解是反应类风湿关节炎与骨软骨炎时候软骨降解的特异指标，这是影响了全球15%人口的发病率很高使人衰弱的关节疾病。

2005年4月《关节炎和风湿》期刊上刊登了这种免疫检测方法的详细内容。这种检测方法是由Synarc公司研制开发的，该公司是密集分子指标以及药理学、生物科技临床实验影象检查的领先服务供应商。

里昂Syncart分子指标服务副总裁兼总经理Patrick Garnero博士说：“Syncart能够帮助鉴别早期关节炎患者，这些患者处于可能快速进展至关节病变，因此需要激进性结构重建治疗。通过鉴别出用于临床试验的理想指标，这种新型生化指标能够帮助减少研制保全患关节炎的关节完整性药物的时间和成本。”

Biomarker of Cartilage Degradation
 
A novel biochemical marker of joint-tissue breakdown is designed for use in clinical trials of new therapies for arthritis.

The immunoassay, called Syncart (helix-II), shows urinary degradation fragment of type II collagen. The breakdown of type II collagen is a specific indicator of cartilage destruction in rheumatoid arthritis and osteoarthritis, two highly prevalent and debilitating joint diseases collectively afflicting more than 15% of the world’s population.

Details on the immunoassay were provided in the April 2005 issue of Arthritis and Rheumatism. The immunoassay was developed by Synarc, Inc. (Lyon, France), a leading provider of centralized molecular marker and imaging services for clinical trials of the pharmaceutical, biotechnology, and medical devices industries.

“Syncart helps identify early arthritis patients who are at high risk of rapidly progressive joint destruction and therefore in need of aggressive structure-modifying therapy,” explained Patrick Garnero, DSc., Ph.D., vice president and general manager of molecular marker services for Synarc in Lyon. “By identifying ideal candidates for clinical trials, this new biochemical marker helps reduce the time and cost of drug development aimed at preserving joint integrity in arthritis.”